Previous 10 | Next 10 |
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Vera Therapeutics Inc. (VERA) is expected to report $-0.5 for Q3 2023
Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations provide further safety analysis of Phase 2b and details of pivotal Phase 3 clinical trial de...
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s m...
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN...
BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s m...
2023-08-17 17:47:04 ET Summary Vera Therapeutics is developing atacicept, a treatment for IgA nephropathy, which showed positive results in Phase 2b trials. The company has strong financials with a cash runway of over two years, but posted an increased net loss in the recent quart...
2023-08-16 14:06:02 ET More on Vera Therapeutics Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target Vera: Repurposed Molecule Program Does Not Impress Novartis deal to buy Chinook rallies Vera Therapeutics Vera Therapeutics slips on $75M...
2023-08-10 12:05:47 ET Vera Therapeutics press release ( NASDAQ: VERA ): Q2 GAAP EPS of -$0.46 beats by $0.23 . Vera reported $181.0 million in cash, cash equivalents, and marketable securities as of June 30, 2023. For further details see: Vera Therapeutics G...
Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60 th ERA Congress Initiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgAN Strong balance sheet e...
News, Short Squeeze, Breakout and More Instantly...
Vera Therapeutics Inc. Company Name:
VERA Stock Symbol:
NASDAQ Market:
Vera Therapeutics Inc. Website:
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L....
2024-06-15 11:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy ...